Jeff Bezos's Prometheus raises $12B to build an 'artificial general engineer' for the physical world

The new round values the physical AI startup that aims to automate heavy engineering and drug design at $41 billion.

Prometheus, a physical AI startup, has raised $12 billion in funding at a valuation of $41 billion. The company was co-founded by Jeff Bezos and Vik Bajaj, the former co-founder of Verily, Google's life sciences unit. This funding round was led by Bezos himself, with participation from other investors. The $12 billion investment is one of the largest funding rounds for a private company in recent history.

The development of an artificial general engineer by Prometheus could lead to significant advancements in fields such as heavy engineering and drug design, potentially reducing costs and increasing efficiency. This could result in lower prices for consumers, particularly in the pharmaceutical industry, where drug development costs are often passed on to patients. For instance, a reduction in drug development costs could lead to more affordable healthcare options. The impact of Prometheus's technology on the pharmaceutical industry will be closely watched.

The concept of artificial general intelligence has been around for decades, but recent advancements in machine learning and computer power have made it more feasible. Companies like Google and Microsoft have been investing heavily in AI research, and the entry of Jeff Bezos into the field is a significant development. Prometheus's focus on physical AI, which combines machine learning with physical systems, is a unique approach that has garnered significant attention from investors. The company's valuation is a testament to the growing interest in AI startups.

Prometheus is expected to use the funding to expand its team and develop its technology further. The company's progress will be closely watched, particularly in the context of its potential to disrupt traditional industries. A key milestone to watch for is the company's planned demonstration of its artificial general engineer, which is expected to take place later this year. Interestingly, Vik Bajaj, the co-founder of Prometheus, has a background in biology, which could indicate that the company's technology has potential applications in fields beyond engineering and drug design.